Andrew Penn, MS, PMHNP-BC

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA · Full program

• DebatePsychedelic Therapy After the Executive Order: Now What?

  September 15, 2026

  Opening-afternoon multidisciplinary panel pairing a patient's lived-experience story with a policy update on how the recent executive order and existing regulatory frameworks may shape near-term clinical use of psychedelic therapies.

  Practice, Policy & WorkforcePsychedelics

• SymposiumCannabis Use and Mental Illness: What We Now Know (and Don't)

  September 15, 2026

  Updates clinicians on cannabis-induced psychosis, mood effects, and dose-response data amid rising THC potency, with practical tapering strategies and treatment pathways for cannabis use disorder.

  Cannabis & CannabinoidsSchizophrenia & PsychosisSubstance Use Disorders

• SymposiumNot All Delusions are Schizophrenia: Understanding Delusional Disorders and the Overlap with Substance Induced Psychosis

  September 16, 2026

  Uses a historic case to teach differential diagnosis of psychosis beyond schizophrenia — substance-induced, delusional, and medical causes — including temporal analysis, labs, and imaging.

  Measurement-Based Care & DiagnosisSchizophrenia & PsychosisSubstance Use Disorders

• SymposiumMasterClass: Unlocking the Doors of Depression: Neuroplastic and Psychedelic Therapies in MDD

  September 17, 2026

  Examines glutamatergic and serotonergic neuroplasticity pathways and the evidence base for investigational psychedelic and psychedelic-assisted therapies in major depression.

  DepressionNeuroscience & MechanismsPsychedelics

• SymposiumMasterClass: GAD Care Reimagined: Current Best Practices and the Emerging Role of Psychedelics

  September 18, 2026

  Pairs a review of current GAD standards of care with the therapeutic rationale and emerging evidence for investigational psychedelic compounds in anxiety.

  Anxiety DisordersPsychedelics

• SymposiumPsychedelics in Psychiatry: Where the Evidence Stands Today and What Comes Next

  September 18, 2026

  Evidence-focused update on psychedelic-assisted therapy trials, regulatory developments, and safety considerations, emphasizing separation of validated data from public enthusiasm.

  Drug Pipeline & Clinical TrialsPsychedelics